1. |
|
|
2. |
|
|
3. |
|
|
4. |
- Brumovsky, P, et al.
(författare)
-
Neuropeptide tyrosine and pain
- 2007
-
Ingår i: Trends in pharmacological sciences. - : Elsevier BV. - 0165-6147. ; 28:2, s. 93-102
-
Tidskriftsartikel (refereegranskat)
|
|
5. |
- Hokfelt, T, et al.
(författare)
-
CCK-ergic mechanisms in sensory systems
- 2001
-
Ingår i: Scandinavian journal of clinical and laboratory investigation. Supplementum. - 0085-591X. ; 61234, s. 69-74
-
Tidskriftsartikel (refereegranskat)
|
|
6. |
|
|
7. |
|
|
8. |
|
|
9. |
|
|
10. |
|
|
11. |
|
|
12. |
|
|
13. |
|
|
14. |
|
|
15. |
|
|
16. |
|
|
17. |
|
|
18. |
|
|
19. |
- Shi, TJS, et al.
(författare)
-
Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain
- 2008
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 1091-6490. ; 105:50, s. 20004-20008
-
Tidskriftsartikel (refereegranskat)abstract
- Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ß3 (PLCß3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.
|
|
20. |
|
|
21. |
|
|
22. |
|
|
23. |
|
|